Cervical cancer therapeutic vaccine based on listeria monocytogenes

By constructing a backcomplement plasmid without Amp resistance gene and inserting the cervical cancer antigen gene, a therapeutic vaccine for cervical cancer is prepared, and the existing vaccine has solved the problems of long and poor immunity cycles and poor results, and an effective solution for cervical cancer treatment is achieved.

CN118903399APending Publication Date: 2024-11-08深圳市青华检验有限公司

Patent Information

Application Number
CN202410887558.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-03
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing Listeria vaccine has the disadvantages of long immune cycles and poor immune effects in the treatment of cervical cancer, and lacks a Listeria vector vaccine with reliable validation and simple preparation method.

Method used

By reverse PCR and seamless clonal ligation method, the backcomplement plasmid without Amp resistance gene was constructed, the cervical cancer antigen gene was inserted, and the therapeutic candidate vaccine for cervical cancer was prepared in singly or Listeria sheep, and biologically performed Test and treatment effect screening to obtain a therapeutic vaccine for cervical cancer.

Benefits of technology

The preparation method of a therapeutic vaccine for cervical cancer has been simple and verified, with better therapeutic effects, and the vaccine is stable in vitro, has high safety and good immunogenicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903399A_ABST
    Figure CN118903399A_ABST
Patent Text Reader

Abstract

The invention discloses a cervical cancer therapeutic vaccine based on listeria monocytogenes, which is prepared by the following steps: replacing an Amp resistance gene on a pCW-LMda 1-Amp back-compensation plasmid with an asd nutrition gene through a reverse PCR (Polymerase Chain Reaction) and seamless cloning connection method, and constructing to obtain a back-compensation plasmid pCW-LMda 1-Ampfree without containing the resistance gene; a cervical cancer antigen gene is inserted into the back-filling plasmid pCW-LMda 1-Ampfree through methods of enzyme digestion, PCR (Polymerase Chain Reaction) and seamless cloning connection, so that the back-filling plasmid pCW-HPVXXX-LMda 1-Ampfree is constructed; the method comprises the following steps: transferring a back-supplement plasmid pCW-HPVXXX-LMda l-Ampfree into a monoproliferation and / or sheep listeria monocytogenes auxotrophic strain, so as to obtain a cervical cancer therapeutic candidate vaccine; and carrying out biological detection and treatment effect screening on the cervical cancer therapeutic candidate vaccine to obtain the cervical cancer therapeutic vaccine. The preparation method of the therapeutic vaccine is simple, and the therapeutic vaccine has a better therapeutic effect through effect verification and screening.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological technology, and in particular to a Listeria-based therapeutic vaccine for cervical cancer. Background Art

[0002] Cervical cancer is the most common gynecological malignancy. The peak age for carcinoma in situ is 30 to 35 years old, and for invasive cancer it is 45 to 55 years old. In recent years, the incidence has tended to be younger. The widespread use of cervical cytology screening in recent decades has enabled the early detection and treatment of cervical cancer and precancerous lesions, and the incidence and mortality of cervical cancer have declined significantly. Traditional methods for treating cancer are mainly surgical resection, radiotherapy, chemotherapy and therapeutic vaccines. Surgical resection, radiotherapy and chemotherapy are prone to metastasis and recurrence. In comparison, the advantage of vaccine therapy is that it causes less damage to the body and has low toxicity. Currently, the vaccines used for tumors are mainly traditional inactivated vaccines and subunit vaccines, which have disadvantages such as long immune cycle and poor immune effect.

[0003] Bacteria-based vaccines have significant advantages in delivering exogenous antigens, including low production costs, high genetic stability, good safety, and highly effective anti-tumor effects. The Listeria balanced lethal system is a green vector system. The Listeria balanced lethal system may have better immune effects due to the high copy characteristics of the plasmid. The existing technology lacks a Listeria vector vaccine with reliably verified effects and simple preparation methods.

[0004] Therefore, the prior art still needs to be improved and developed. Summary of the invention

[0005] The present invention provides a Listeria-based therapeutic vaccine for cervical cancer, aiming to solve the technical problems existing in the Listeria vaccine mentioned in the background technology.

[0006] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:

[0007] The present invention provides a Listeria-based cervical cancer therapeutic vaccine, which is prepared by the following method:

[0008] The Amp resistance gene on the pCW-LMdal-Amp complementation plasmid was replaced with the asd nutritional gene by the method of inverse PCR and seamless cloning and connection, and the complementation plasmid pCW-LMdal-Ampfree without the Amp resistance gene was constructed;

[0009] Insert the cervical cancer antigen gene into the complementing plasmid pCW-LMdal-Ampfree by enzyme digestion, PCR and seamless cloning to construct the complementing plasmid pCW-HPVXXX-LMdal-Ampfree;

[0010] The complementing plasmid pCW-HPVXXX-LMdal-Ampfree is transferred into Listeria monocytogenes auxotrophic strain and / or Listeria ovis auxotrophic strain to obtain a candidate therapeutic vaccine for cervical cancer;

[0011] Conduct biological testing and therapeutic effect screening on candidate cervical cancer therapeutic vaccines to obtain cervical cancer therapeutic vaccines.

[0012] In an optional embodiment of the present invention, the cervical cancer antigen gene includes phly-SS-gp33-HA-E6E7-gp61.

[0013] In an optional embodiment of the present invention, the biological detection and treatment effect screening of the candidate cervical cancer therapeutic vaccine to obtain the cervical cancer therapeutic vaccine comprises:

[0014] PCR was used to detect the in vitro stability of the complementing plasmid pCW-HPVXXX-LMdal-Ampfree carried by the candidate cervical cancer therapeutic vaccine;

[0015] The basic biological characteristics of the candidate therapeutic vaccine for cervical cancer were determined by biochemical reactions, in vitro growth, and hemolysis experiments;

[0016] The secretory proteins and bacterial proteins of the cervical cancer therapeutic candidate vaccine were extracted, and the in vitro expression of the target protein of the cervical cancer therapeutic candidate vaccine was verified by WB experiment.

[0017] In an optional embodiment of the present invention, the biological detection and treatment effect screening of the candidate cervical cancer therapeutic vaccine to obtain the cervical cancer therapeutic vaccine further comprises:

[0018] The LD50 of the candidate therapeutic vaccine for cervical cancer was determined by using the modified Coeur method. The safety of the candidate therapeutic vaccine for cervical cancer was evaluated by measuring the bacterial load in the liver / spleen / lung, the liver / spleen / lung organ index, the ALT and AST, the weight change of mice, and the preparation and observation of liver / spleen / lung pathological sections.

[0019] The in vivo stability of the candidate therapeutic vaccine for cervical cancer was tested by PCR using colonies grown on BH I plates of liver / spleen / lung grinding drop plates at different time points as templates;

[0020] Detection of CD4 in mouse spleen cells by flow cytometry + T cells and CD8 + IFN-γ in T cells + IL-2 + IL-12 + and TNF-α +The ratio of cells was used to determine the immunogenicity of the cervical cancer therapeutic vaccine candidate.

[0021] In an optional embodiment of the present invention, the biological detection and treatment effect screening of the candidate cervical cancer therapeutic vaccine to obtain the cervical cancer therapeutic vaccine further comprises:

[0022] The cervical cancer tumor-bearing mouse model was established by subcutaneous injection of TC-1 cells, and the therapeutic effect of the candidate cervical cancer therapeutic vaccine was determined by LM-LI-LM combined immunization.

[0023] The LM-LI-LM combination immunization method is the first immunization with Listeria monocytogenes cervical cancer therapeutic candidate vaccine, the second immunization with Listeria monocytogenes cervical cancer therapeutic candidate vaccine, and the third immunization with Listeria monocytogenes cervical cancer therapeutic candidate vaccine, and the interval between each immunization is 7 days.

[0024] In an optional embodiment of the present invention, the biological detection and treatment effect screening of the candidate cervical cancer therapeutic vaccine to obtain the cervical cancer therapeutic vaccine further comprises:

[0025] Two immunization methods, intratumor injection and tail vein injection, were used to compare the effects of different immunization methods on the therapeutic efficacy of cervical cancer therapeutic vaccine candidates.

[0026] Beneficial effects: The present invention discloses a Listeria-based cervical cancer therapeutic vaccine, which is prepared by the following methods: replacing the Amp resistance gene on the pCW-LMda l-Amp complementation plasmid with the asd nutritional gene by the method of reverse PCR and seamless cloning connection, constructing a complementation plasmid pCW-LMda l-Ampfree without the resistance gene; inserting the cervical cancer antigen gene into the complementation plasmid pCW-LMda l-Ampfree by the method of enzyme cutting, PCR and seamless cloning connection to construct the complementation plasmid pCW-HPVXXX-LMda l-Ampfree; transferring the complementation plasmid pCW-HPVXXX-LMda l-Ampfree into the mono-hypertrophic and / or ovine Listeria auxotrophic strains to obtain a cervical cancer therapeutic candidate vaccine; performing biological detection and therapeutic effect screening on the cervical cancer therapeutic candidate vaccine to obtain a cervical cancer therapeutic vaccine. The therapeutic vaccine preparation method of the present invention is simple and has been screened for effect verification, and has a better therapeutic effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is a schematic diagram of the structure of a Listeria-based cervical cancer therapeutic vaccine of the present invention.

[0028] Figure 2 The spleen cells of each group of the present invention are CD4 + I FN-γ+ T cells and CD8 + I FN-γ + Schematic diagram of T cell ratio determination results.

[0029] Figure 3 The spleen cells of each group of the present invention are CD4 + I FN-γ + T cells and CD8 + I FN-γ + Statistical graph of T cell assay results.

[0030] Figure 4 The spleen cells of each group of the present invention are CD4 + IL-2 + T cells and CD8 + IL-2 + Schematic diagram of T cell ratio determination results.

[0031] Figure 5 The spleen cells of each group of the present invention are CD4 + IL-2 + T cells and CD8 + IL-2 + Statistical graph of T cell assay results.

[0032] Figure 6 The spleen cells of each group of the present invention are CD4 + IL-12 + T cells and CD8 + IL-12 + Schematic diagram of T cell ratio determination results.

[0033] Figure 7 The spleen cells of each group of the present invention are CD4 + IL-12 + T cells and CD8 + IL-12 + Statistical graph of T cell assay results.

[0034] Figure 8 The spleen cells of each group of the present invention are CD4 + TNF-α + T cells and CD8 + TNF-α + Statistical graph of T cell assay results.

[0035] Fig. 9 The spleen cells of each group of the present invention are CD4 + TNF-α + T cells and CD8 + TNF-α + Statistical graph of T cell assay results.

[0036] Fig.10 This is a graph showing the changes in tumor volume in the PBS group (tail vein immunization) of the present invention.

[0037] Fig.11 This is a graph showing the changes in tumor volume in the vector strain group (tail vein immunization) of the present invention.

[0038] Fig.12 This is a graph showing the changes in tumor volume in the vaccine strain group of the present invention (tail vein immunization).

[0039] Fig.13 This is a graph showing the changes in tumor volume in the vaccine strain group (intratumor injection group) of the present invention.

[0040] Fig.14 This is a graph showing the changes in tumor volume in the non-equilibrium lethal systemic vaccine strain group (tail vein immunization) of the present invention.

[0041] Fig.15 It is a record diagram of the median survival time of each experimental group of the present invention. DETAILED DESCRIPTION

[0042] In order to make the purpose, technical solution and effect of the present invention clearer and more specific, the present invention is further described in detail with reference to the accompanying drawings and examples. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0043] See also Figure 1 The present invention provides a Listeria-based cervical cancer therapeutic vaccine, which is prepared by the following method:

[0044] S100, the Amp resistance gene on the pCW-LMdal-Amp complementing plasmid was replaced with the asd nutritional gene by reverse PCR and seamless cloning connection to construct the complementing plasmid pCW-LMdal-Ampfree without the Amp resistance gene.

[0045] In step S100 of the present invention, first, the E. coli DH5α-asd carrying the plasmid PYA876 containing the asd gene, the E. coli DH5α-LMdal carrying the pCW-LMdal-Amp complementing plasmid, and the E. coli DH5αΔasd lacking the asd nutritional gene, which are stored in glycerol at -80°C, are revived by using broth, and the PYA876 plasmid and pCW-LMdal-Amp complementing plasmid are obtained from the revived E. coli DH5α-asd and E. coli DH5α-LMdal by centrifugal adsorption. dal-Amp complementing plasmid, and then the PYA876 plasmid and pCW-LMdal-Amp complementing plasmid were amplified by reverse PCR and recovered to obtain the pCW-LMdal-Amp complementing plasmid linear vector and asd gene fragment; finally, the pCW-LMdal-Amp complementing plasmid linear vector and asd gene fragment were introduced into the competent Escherichia coli DH5αΔasd through the seamless cloning system to obtain the Escherichia coli αΔasd containing the complementing plasmid pCW-LMdal-Ampfree.

[0046] S200, inserting the cervical cancer antigen gene into the complementing plasmid pCW-LMdal-Ampfree by enzyme digestion, PCR, and seamless cloning connection to construct the complementing plasmid pCW-HPVXXX-LMdal-Ampfree, wherein the cervical cancer antigen gene includes phly-SS-gp33-HA-E6E7-gp61.

[0047] In step S200, the Escherichia coli DH5α-HPV carrying the cervical cancer antigen gene plasmid is first resuscitated in broth, and then the cervical cancer antigen gene plasmid and the complementing plasmid pCW-LMdal-Ampfree are extracted from the Escherichia coli DH5α-HPV and the Escherichia coli αΔasd containing the complementing plasmid pCW-LMdal-Ampfree obtained in step S100 by the same method as in step S100; then the complementing plasmid pCW-LMdal-Ampfree is subjected to enzyme digestion and gel recovery to obtain a purified pCW-LMdal-Ampfree linear vector, and then the cervical cancer antigen gene plasmid is amplified and gel recovered to obtain a purified cervical cancer antigen gene fragment, and finally the cervical cancer antigen gene fragment is inserted into the pCW-LMdal-Ampfree linear vector to obtain the complementing plasmid pCW-HPVXXX-LMdal-Ampfree.

[0048] S300. Transfer the complementing plasmid pCW-HPVXXX-LMda l-Ampfree into the auxotrophic strain of Listeria monocytogenes and / or the auxotrophic strain of Listeria ovis to obtain a candidate therapeutic vaccine for cervical cancer.

[0049] In step S300, a competent Listeria monocytogenes auxotrophic strain and a competent Listeria ovis auxotrophic strain are first prepared, and then the complementing plasmid pCW-HPVXXX-LMda l-Ampfree is electroporated into the competent Listeria monocytogenes auxotrophic strain and / or the competent Listeria ovis auxotrophic strain to obtain a cervical cancer therapeutic candidate vaccine. In the present invention, based on the different vectors of Listeria, the cervical cancer therapeutic candidate vaccine is also divided into Listeria monocytogenes cervical cancer therapeutic candidate vaccine (LMΔΔdd:da l-HPVXXX (e.g., E6E7)-Ampfree, abbreviated as LM) and Listeria ovis cervical cancer therapeutic candidate vaccine (LIΔΔdd:da l-HPVXXX (e.g., E6E7)-Ampfree, abbreviated as LI).

[0050] S400, biological detection and therapeutic effect screening of the candidate vaccine for therapeutic cervical cancer are performed to obtain a therapeutic vaccine for cervical cancer. It should be noted that in order to better reflect the effect of the candidate vaccine for therapeutic cervical cancer of the present invention, in addition to constructing a candidate vaccine for therapeutic cervical cancer (vaccine strain), a pure vector strain without an antigen gene is also constructed (also including Listeria monocytogenes vaccine vector strain (LMΔΔdd: da l-Ampfree) and Listeria ovis vaccine vector strain (LIΔΔdd: da l-Ampfree)). The preparation method of the pure vector strain is the same as that of the vaccine strain except for the step of omitting the antigen gene access.

[0051] In step S400, the biological detection and therapeutic effect screening of the candidate cervical cancer therapeutic vaccine to obtain the cervical cancer therapeutic vaccine includes:

[0052] PCR was used to detect the in vitro stability of the complementing plasmid pCW-HPVXXX-LMda l-Ampfree carried by the candidate vaccine for therapeutic cervical cancer. In this step, the constructed candidate vaccine for therapeutic cervical cancer (vaccine strain) and the pure vector strain were inoculated into 5 mL BH I broth, cultured at 37°C and 180 r / min for 18-20 hours, and continuously subcultured for 25 generations according to the culture conditions. The vaccine strain culture liquid of the 1st, 5th, 10th, 15th, 20th, and 25th generations were used to perform PCR to verify the in vitro stability of the plasmid using primers Da l, primers E6E7, and Listeria-specific primers LM and LI; and the vector strain culture liquid of the 1st, 5th, 10th, 15th, 20th, and 25th generations was used to perform PCR to verify the in vitro stability of the plasmid using primers Da l, primers asd, and Listeria-specific primers LM and LI.

[0053] The basic biological characteristics of candidate therapeutic vaccines for cervical cancer were determined through biochemical reactions, in vitro growth, and hemolysis experiments; in this step, the vaccine strains (LMΔΔdd: dal-E6E7-Ampfree and LIΔΔdd: dal-E6E7-Ampfree), vector strains (LMΔΔdd: dal-Ampfree and LIΔΔdd: dal-Ampfree), attenuated strains (LMΔ and LIΔ) and nutritionally deficient strains (LMΔΔdd and LIΔΔdd) were inoculated into 50 mL of BHI broth, cultured at 37°C and 180 r / min, the OD600 of each strain was measured every 1 h, the culture was terminated after 10 h, and the growth curve of the strain was drawn.

[0054] Biochemical reaction determination: The vaccine strain, vector strain and attenuated strain were inoculated on BHI plates and cultured at 37°C for 24 hours; each strain was diluted with 0.45% saline to a McFarland turbidity of 0.4-0.5; VITEK Gram-positive bacteria susceptibility cards were inserted, and the fully automatic strain identification and susceptibility analyzer were used for detection, and the biochemical results were recorded.

[0055] Determination of blood plate growth: The vaccine strain, vector strain and attenuated strain were inoculated on BHI plates and cultured at 37°C for 24 h. Single colonies on the BHI plates where each strain grew were picked and inoculated by puncture and circle on BHI blood plates, and cultured at 37°C for 24 h to observe the growth of each strain on the BHI blood plates.

[0056] Hemolytic titer determination: The vaccine strain, vector strain and attenuated strain were inoculated into 10 mL BHI broth and cultured overnight at 37°C and 180 rpm. The OD of each strain was determined. 600 According to the Listeria concentration formula, the concentration of the bacterial solution of the LM group (LMΔΔdd:dal-E6E7-Ampfree, LMΔΔdd:dal-Ampfree and LMΔ) was adjusted to OD 600 = 1.0, and the concentration of the bacterial solution of the LI group (LIΔΔdd:dal-E6E7-Ampfree, LIΔΔdd:dal-Ampfree and LIΔ) was adjusted to OD 600 = about 0.8; take 5mL of the adjusted bacterial solution and centrifuge it at 16200g for 5min in a 15mL sterile centrifuge tube, and resuspend it in 5mL PBS; dilute the resuspended bacterial solution 1:2 to 2-8 with PBS, take 100μL of each diluted bacterial solution and add it to a 96-well U-shaped plate, and set up a PBS control well at the same time; add 100μL of 1% sheep red blood cells to each well, and culture at 37℃ for 2h. The culture time can be appropriately increased as needed, and take pictures to record the hemolytic titer of each strain.

[0057] The secretory proteins and bacterial proteins of the cervical cancer therapeutic candidate vaccine were extracted, and the in vitro expression of the target protein of the cervical cancer therapeutic candidate vaccine was verified by WB experiment.

[0058] In this step, the steps of extracting secreted proteins include: taking 2 mL of the revived overnight culture solution and inoculating it into 100 mL of BHI broth, culturing at 37°C and 180 r / min; when the OD of the culture solution reaches 600 When OD ≈ 1.0, adjust the LM vaccine strain and the LM non-equilibrium lethal system vaccine strain to the same OD 600 The LI vaccine strain and the LI non-equilibrium lethal system vaccine strain were adjusted to OD 600 value; take 40mL of bacterial solution into a 50mL sterile centrifuge tube, centrifuge at 6000rpm and 4℃ for 15min; take the supernatant and filter it with a 0.22μm filter; add 4mL of saturated TCA to the filtrate, let it stand at 4℃ overnight; centrifuge at 12000rpm and 4℃ for 30min, discard the supernatant; add 20mL of acetone solution stored at 4℃ to dissolve the precipitate in batches, centrifuge at 12000rpm and 4℃ for 10min, discard the supernatant; add 200μL of protein dissolving solution to fully dissolve, dispense 50μL into each tube, and store temporarily at -20℃.

[0059] In this step, the extraction of bacterial protein includes: taking 0.5 mL of the revived overnight culture solution and inoculating it into 10 mL of BHI broth, and culturing at 37°C and 180 r / min; when OD 600 When OD ≈ 0.8, adjust the LM vaccine strain and the LM non-equilibrium lethal system vaccine strain to the same OD 600 The LI vaccine strain and the LI non-equilibrium lethal system vaccine strain were adjusted to OD 600 value; take 5mL of bacterial solution in a 15mL sterile centrifuge tube, centrifuge at 16200g for 2min, and remove the supernatant; add 2mL of autoclaved 1mol / L PBS solution, centrifuge at 13000rpm for 2min, and remove the supernatant; add 300μL of protein resuspension solution, fully dissolve, and place in a metal bath at 37℃ for 2h; add 5mL of ultrapure water, and ultrasonically break under the conditions of 100% amplitude, pulse 5s, and pause 5s until the resuspension is clear and transparent; add 0.5mL of TCA stored at 4℃ and mix well, and let stand at 4℃ for 45min; centrifuge at 4℃, 16200g for 35min, and remove the supernatant; add 20mL of acetone solution stored at 4℃ in batches to fully dissolve the precipitate, centrifuge at 4℃, 16200g for 35min, and discard the supernatant; add 200μL of protein dissolution solution to completely dissolve the precipitate, and dispense 50μL into each tube and store at -20℃ temporarily.

[0060] WB experiment: Gel preparation: Take one tube of secretory protein and bacterial protein melted on ice for each strain, add 10μL SDS-PAGE loading buffer to each tube, mix thoroughly, place in a 100℃ metal bath for 10min, and centrifuge instantly; take an equal volume of 20μL of supernatant after centrifugation in each group and carefully add it to the sample well of the configured SDS-PAGE gel (10% separation gel, 5% stacking gel, 1.5mm), and run electrophoresis at 90V to the dividing line of the stacking gel; adjust the voltage to 120V, run electrophoresis to the appropriate position, and end the electrophoresis to obtain the SDS-PAGE gel.

[0061] Experiment: Take the SDS-PAGE gel after electrophoresis, cut off the concentrated gel, carefully place it in the center of the thick transfer filter paper soaked in pre-cooled 1×Trans-blot turbo 5X transfer buffer, and expel the bubbles; spread an equal area of ​​PVDF membrane activated with methanol on the SDS-PAGE gel, expel the bubbles, and cover it with thick transfer filter paper soaked in pre-cooled 1×Trans-blotturbo 5X transfer buffer; turn it over and place it in the Trans-Blot Turbo transfer box, pour in an appropriate volume of pre-cooled 1×Trans-blotturbo 5X transfer buffer, and cover with a sealing lid; use Trans-Blot Turbo transfer instrument 1.3A Transfer at 25V for 10 minutes, take out the PVDF membrane and put it into the blocking solution containing 5% skim milk powder, gently shake at room temperature for 1.5 hours, and pour out the blocking solution; add an appropriate volume of TBST, shake and wash for 5 minutes, repeat three times, and pour out the supernatant; add anti-HA mouse monoclonal antibody as the primary antibody, incubate at 4°C with gentle shaking overnight, and recover the primary antibody; add an appropriate volume of TBST, shake and wash for 5 minutes, repeat three times, and pour out the supernatant; add horseradish peroxidase-labeled goat anti-mouse IgG (G+H) as the secondary antibody, gently incubate at room temperature for 1 hour, and recover the secondary antibody; add an appropriate volume of TBST, shake and wash for 5 minutes, repeat three times, and pour out the supernatant; use ECL high-sensitivity chemiluminescence color development kit to detect the target band, and iBright imaging system semi-quantitatively observe the experimental results.

[0062] In an optional embodiment of the present invention, the biological detection and treatment effect screening of the candidate cervical cancer therapeutic vaccine to obtain the cervical cancer therapeutic vaccine further comprises:

[0063] The LD50 of the candidate therapeutic vaccine for cervical cancer was determined by the modified Cole method, and the safety of the candidate therapeutic vaccine for cervical cancer was evaluated by measuring the bacterial load in the liver / spleen / lungs, the liver / spleen / lung organ indexes, the ALT and AST, the weight changes of mice, and the preparation and observation of liver / spleen / lung pathological sections.

[0064] LD50 determination:

[0065] Preparation of bacterial solutions of various concentrations: the vaccine strain and the vector strain were inoculated into 5 mL BH I broth respectively, and cultured at 37°C and 180 r / min for 18-20 h to allow them to grow fully; all of them were inoculated into 200 mL BH broth, and cultured overnight at 37°C and 180 r / min, and the OD600 was measured, and the concentration was calculated according to the Listeria concentration formula, and an appropriate amount of bacterial solution was placed in a 15 mL sterile centrifuge tube to meet the expected concentration, and centrifuged at 4°C and 16500g for 5 min, and the supernatant was discarded to remove impurities in the culture medium and improve the purity of the bacterial solution; 5 mL of sterile PBS was added for resuspending and washing, and the solution was centrifuged at 4°C and 16500g for 5 min, and the supernatant was discarded, and 5 mL of sterile PBS was added for resuspending; 10-fold dilution of each group of bacteria was taken, and plated on a BH I plate, and each concentration was repeated three times, and cultured at 37°C for 24 h, and the actual concentration of each group of bacterial solution was counted and calculated.

[0066] Grouping and immunization: 100 μL of each concentration of bacterial solution was inoculated by tail vein immunization. Ten mice that had been adaptively cultured for one week were inoculated with each concentration, for a total of 120 mice.

[0067] Determination: The survival rate of mice immunized with different strains and different bacterial concentrations was recorded for 10 consecutive days. The LD50 of the vaccine strain and the vector strain was calculated using the modified Koch method based on the actual concentration of each strain and the survival rate of each group of mice counted on the drop plate.

[0068] Liver / spleen / lung organ index determination:

[0069] Preparation of bacterial solution: The bacterial solution was prepared by LD50 determination, and the final resuspension concentration was the concentration corresponding to 0.1LD50.

[0070] Immunization: The calculated LD50 of the vaccine strain and the vector strain were used to immunize mice via the tail vein with an inoculation dose of 0.1 LD50.

[0071] Determination of changes in organ indexes of liver, spleen, and lungs: Aseptically weigh the liver, spleen, and lungs of each group of mice on days 0, 1, 3, 5, 7, 9, and 14 after immunization, and record the corresponding body weights of the mice. Calculate the changes in organ indexes of liver, spleen, and lungs of mice at different stages after immunization with vaccine strains and vector strains according to the formula, and repeat three times independently.

[0072] Determination of bacterial load in liver / spleen / lung: The vaccine strains and vector strains were used to immunize mice through the tail vein at an immunization dose of 0.1LD50. Under sterile conditions, the livers, spleens, and lungs of 3 mice in each group were taken on the 1st, 3rd, 5th, 7th, 9th, and 14th days, ground in an appropriate volume of sterile 0.1% Triton X-100 solution, diluted 10 times with sterile 0.1% TritonX-100 solution or PBS solution, plated on BHI plates, and cultured at 37°C for 24 hours. The number of colonies was recorded, and the bacterial load in the liver, spleen, and lungs of mice at different stages after immunization with the vaccine strains and vector strains was calculated. This process was repeated three times independently.

[0073] Determination of serum ALT and AST: The vaccine strain and the vector strain were used to immunize mice through the tail vein with an immunization dose of 0.1LD50. Under sterile conditions, eye blood was collected from 3 mice in each group on days 0, 1, 3, 5, 7, 9, and 14. The blood was immediately allowed to stand at room temperature for 3 h. The tube rack was not moved during the standing process in order to obtain more serum for subsequent experiments. The serum was collected by centrifugation at 3000 rpm for 20 min to avoid absorbing red blood cells in the lower layer and affecting the experiment. The changes in ALT and AST of mice immunized with the vaccine strain and the vector strain at different stages were detected by ALT and AST detection kits and a fully automatic biochemical analyzer.

[0074] Preparation and observation of pathological sections of liver, spleen and lung: Four groups of mice were immunized via the tail vein with the vaccine strain and the vector strain at a 0.1LD50 immunization dose. At the same time, a control group was set up with PBS adaptive culture for one week. Under sterile conditions, the liver, spleen and lungs of mice in each group were taken on the 3rd and 14th days, fixed in an appropriate volume of 4% tissue fixative for 48 hours, and sent to a biological company for embedding, sectioning, and HE staining. The prepared sections were also subjected to pathological analysis and scoring.

[0075] Observation of body weight changes: The vaccine strain and the vector strain were immunized with 0.1LD50 immunization dose through the tail vein of each group of mice, and the body weight changes of each group of mice were recorded for 14 consecutive days to determine the extent of the effect of the vaccine strain on the body weight of mice.

[0076] The in vivo stability of the candidate therapeutic vaccine for cervical cancer was detected by PCR using colonies grown on the BH I plate of the liver / spleen / lung grinding drop plate at different time points as templates. In this step, any colonies grown on the plates for measuring bacterial loads in the liver, spleen, and lung of the vaccine strain on the 1st, 3rd, 5th, and 7th days were taken, and PCR verification was performed using E6E7 primers, Da l primers, asd primers, and Listeria-specific primers LM and LI; the vector strain was also taken. Any colonies grown on the plates for measuring bacterial loads in the liver, spleen, and lung on the 1st, 3rd, 5th, and 7th days were used for PCR verification using Dal primers, asd primers, and Listeria-specific primers LM and LI.

[0077] Detection of CD4 in mouse spleen cells by flow cytometry + T cells and CD8+ IFN-γ in T cells + IL-2 + IL-12 + and TNF-α + The ratio of cells was used to determine the immunogenicity of the cervical cancer therapeutic vaccine candidate.

[0078] In this step, the immunization is based on the LD50 of the vaccine strain and the vector strain calculated above, and the mice are immunized with 0.1 LD50 of bacteria through the tail vein every other week for a total of three times;

[0079] Preparation of spleen cell suspension: Aseptically take the spleen of each group of mice on the 9th day after the third immunization and place it in 1mL 1640 containing 2% double antibody, and store it on ice to maintain the activity of mouse spleen; transfer each tube to a sterile nylon mesh, add 4-5mL 1640 containing 2% double antibody, and grind gently and thoroughly under sterile conditions; rinse the grinding plate with a small amount of 1640, and transfer all the liquid to a 15mL sterile centrifuge tube, centrifuge at 4℃1300rpm for 5min, gently discard the supernatant, and prevent Stop cell loss and remove impurities at the same time; gently tap the bottom of the centrifuge tube to loosen the cell pellet, add 5mL of red blood cell lysis buffer and react at room temperature for 5min, immediately add an equal volume of 1640 containing 2% double antibody to terminate the reaction, centrifuge at 4℃1300rpm for 5min, and gently remove the supernatant to remove excess lysis buffer; after repeating the cell dispersion operation, add 5mL of 1640 containing 2% double antibody again, centrifuge again under the same conditions, gently remove the supernatant to remove impurities, and repeat washing to improve purity; add 3mL of 1640 complete culture medium to resuspend and store at room temperature.

[0080] Peptide stimulation and flow staining: The prepared spleen cell suspension was added to a 96-well U-shaped plate in groups, 50 μL per well. At the same time, a corresponding negative control group was set up for each sample, and 3 samples were randomly selected as positive controls; 50 μL of antigen peptide (E6E7 peptide) stimulation mixture was added to the sample wells, 50 μL of negative stimulation mixture was added to the negative control wells, and 50 μL of positive stimulation mixture was added to the positive control wells; the 96-well U-shaped plate was gently shaken to ensure that the cells were evenly distributed at the bottom of the wells to avoid uneven staining due to uneven cell concentration. Culture in an incubator for 5-6 hours; after the culture period, centrifuge at 1300 rpm for 5 minutes, and vortex to disperse the cells at the bottom of the 96-well plate again; add 50 μL of extracellular antibody mixture to the sample wells, negative control wells and positive control wells in the dark, and incubate at 4°C in the dark for 30 minutes; add 150 μL of PBS solution containing 2% fetal bovine serum to each well in the dark, centrifuge at 300g in the dark for 5 minutes, gently discard the supernatant, and vortex; add 150 μL of Fluxation / Permeabilization solution to each well in the dark, and fix and permeabilize the membrane at 4°C in the dark for 20 minutes; add 100 μL of 1×BD Perm / Wash in the dark TM Buffer, centrifuge at 500g in dark for 5 min, gently discard the supernatant, vortex shake; add 50 μL of intracellular antibody mixture in dark, incubate at 4℃ in dark for 45 min; add 200 μL of 1×BD Perm / Wash in dark TM Buffer, centrifuge at 500g in dark for 5 min, gently discard the supernatant, vortex and shake, repeat once; add 200 μL 1×BD Perm / Wash in dark. TM Buffer, store at 4℃ in the dark.

[0081] Detection on the flow cytometer: Resuspend the cells temporarily stored at 4°C in the dark, transfer each well to a clean 1.5mL eppendorf tube, and detect on the NovoCyte flow cytometer.

[0082] Immunogenicity assay results:

[0083] Group A in the relevant figures is the PBS group (PBS→PBS→PBS), group B is the LM vector strain immunization group (LMΔΔdd:dal-Ampfree→LMΔΔdd:dal-Ampfree→LMΔΔdd:dal-Ampfree), group C is the LI vector strain immunization group (LIΔΔdd:dal-Ampfree→LIΔΔdd:dal-Ampfree→LIΔΔdd:dal-Ampfree), and group D is the LM vaccine strain immunization group (LMΔΔdd:dal-E6E7-Ampfree→LMΔΔdd :dal-E6E7-Ampfree→LMΔΔdd:dalE6E7-Ampfree), Group E was the LI vaccine strain immunization group (LIΔΔdd:dal-E6E7-Ampfree→LIΔΔdd:dal-E6E7-Ampfree→LIΔΔdd:dal-E6E7-Ampfree); Group F was the combined immunization group (LMΔΔdd:dal-E6E7-Ampfree→LIΔΔdd:dal-E6E7-Ampfree→LMΔΔdd:dal-E6E7-Ampfree).

[0084] (1) CD4 + IFN-γ + T cells and CD8 + IFN-γ + T cell ratio

[0085] Figure 2 The scatter plots shown are the CD4 + IFN-γ + T cells and CD8 + IFN-γ + Schematic diagram of T cell ratio determination results. Compared with groups A and B, group D has a higher splenocyte CD4 + IFN-γ + The T cell ratio increased, and the difference was statistically significant; compared with groups A and C, the spleen cell CD4 + IFN-γ + The T cell ratio also increased, and the difference was statistically significant; the CD4 + IFN-γ + The T cell ratio showed an increasing trend, but the difference was not statistically significant. Figure 3 (b) The number of splenocytes in group D was significantly higher than that in groups A and B. + IFN-γ + The ratio of T cells in group E showed an upward trend, but the difference was not statistically significant. Compared with groups A and C, the ratio of splenocytes CD8 + I FN-γ +The ratio of T cells increased, and the difference was statistically significant; the CD8 + I FN-γ + The T cell ratio increased and the difference was statistically significant, but compared with group E, the spleen cells only tended to increase and the difference was not statistically significant. Figure 3 (c) as shown.

[0086] (2) CD4 + IL-2 + T cells and CD8 + IL-2 + T cell ratio:

[0087] Figure 4 The scatter plots shown are the CD4 + IL-2 + T cells and CD8 + IL-2 + Schematic diagram of T cell ratio determination. CD4 of spleen cells in group D was higher than that in group A. + IL-2 + The T cell ratio increased, the difference was statistically significant, and there was an upward trend compared with the corresponding group B, but there was no statistical difference; compared with group A and the corresponding group C, the spleen cell CD4 + IL-2 + The ratio of T cells also increased, and the difference was statistically significant; compared with group D, the ratio of spleen cell CD4 + IL-2 + The T cell ratio increased, the difference was statistically significant, and there was an upward trend compared with group E, but there was no statistical difference. Figure 5 Compared with group A and the corresponding group B, group D had a higher number of splenocytes CD8 + IL-2 + The ratio of T cells in group E was significantly higher than that in group A and group C. + IL-2 + Compared with group D and group E, the ratio of CD8 + IL-2 + The T cell ratio increased significantly, and the difference was statistically significant. Figure 5 As shown in (c).

[0088] (3) CD4 + IL-12 + T cells and CD8 + IL-12 + T cell ratio

[0089] Figure 6The scatter plots shown are the CD4 + IL-12 + T cells and CD8 + IL-12 + Schematic diagram of T cell ratio determination. Compared with group A and their corresponding groups B and C, the CD4 + IL-12 + T cells increased, and the differences were statistically significant; compared with groups D and E, the number of spleen cell CD4 + IL-12 + The T cell ratio was slightly lower, but not statistically significant. Figure 7 As shown in (b). Group D spleen cells and CD8 + IL-12 + The ratio of T cells also increased compared with group A and group B, and the difference was statistically significant. The ratio of spleen cells and CD8 + IL-12 + The T cell ratio was significantly different from that of group C, but showed an increasing trend compared with group A, but there was no statistical difference. Compared with groups D and E, the spleen cells and CD8 + IL-12 + The T cell ratio was slightly decreased, but there was no statistical difference. Figure 7 As shown in (c).

[0090] (4) CD4 + TNF-α + T cells and CD8 + TNF-α + T cell ratio

[0091] Figure 8 The scatter plots shown are the CD4 + TNF-α + T cells and CD8 + TNF-α + Schematic diagram of T cell ratio determination. D Compared with group A and corresponding group B, splenocyte CD4 + TNF-α + The T cell ratio increased, but the difference was not statistically significant; the CD4 + TNF-α + Compared with groups A and C, the ratio of T cells in group F was higher, and the difference was statistically significant. + TNF-α + The T cell ratio increased significantly, and the difference was statistically significant. Fig. 9 As shown in (b). Group D splenocyte CD8 + TNF-α+ Compared with group A and the corresponding group B, the ratio of T cells showed an upward trend, but the difference was not statistically significant. Compared with group A and the corresponding group C, the ratio of spleen cells CD8 + TNF-α + The ratio of T cells increased, and the difference was statistically significant; compared with groups D and E, the CD8 + TNF-α + The T cell ratio increased and the difference was statistically significant. Fig. 9 As shown in (c).

[0092] The results of flow cytometry showed that the expression of I NF-γ in spleen cell suspension of LMΔΔdd:da l-E6E7-Ampfree alone group, LIΔΔdd:da l-E6E7-Ampfree alone group and combined immunization group was significantly higher than that of LMΔΔdd:da l-E6E7-Ampfree alone group. + IL-2 + , IL-12 + TNF-α + The cell ratio was higher than that of the PBS group and the vector strain group, indicating that the vaccine strain had good immunogenicity and the combined immunization method was superior.

[0093] In an optional embodiment of the present invention, the biological detection and treatment effect screening of the candidate cervical cancer therapeutic vaccine to obtain the cervical cancer therapeutic vaccine further comprises:

[0094] A cervical cancer tumor-bearing mouse model was established by subcutaneous injection of TC-1 cells, and the therapeutic effect of the cervical cancer therapeutic candidate vaccine was determined by the LM-LI-LM combined immunization method; the LM-LI-LM combined immunization method was the first immunization with Listeria monocytogenes cervical cancer therapeutic candidate vaccine (LM), the second immunization with Listeria monocytogenes cervical cancer therapeutic candidate vaccine (LI), and the third immunization with Listeria monocytogenes cervical cancer therapeutic candidate vaccine (LM), and the interval between each immunization was 7 days; and two immunization methods, intratumor injection and tail vein injection, were used to compare the effects of different immunization methods on the therapeutic effect of the cervical cancer therapeutic candidate vaccine.

[0095] Recovery of TC-1 cells: Take a tube of TC-1 cells frozen in liquid nitrogen, thaw quickly at 37℃, transfer all of them into 7mL of 1640 culture medium containing 2% double antibody, centrifuge at 1300rpm for 3min at room temperature, discard the supernatant to remove the residual freezing solution; add 8mL of 1640 culture medium containing 2% double antibody to resuspend the cells at the bottom of the tube, centrifuge at 1300rpm for 3min at room temperature, discard the supernatant to ensure purity; add 1mL of 1640 complete culture medium to resuspend, and transfer to a 25cm 2 Cell culture flasks, 37°C CO 2 nourish.

[0096] Passaging of TC-1 cells: Cultivate the cells to be revived to a density of 80%-90%, discard the culture medium, add 3mL sterile PBS to wash the cells, pour out the washing medium, repeat once; add 1mL EDTA-free trypsin to digest at 37℃ for 1min, and immediately add 2mL 1640 complete medium to terminate the digestion; blow off the attached cells completely, transfer all to a 15mL sterile centrifuge tube, centrifuge at 1300rpm for 3min at room temperature, discard the supernatant to remove the residual digestion solution; add 2mL 1640 complete medium to resuspend, and transfer to 2 bottles of 25cm 2 Cell culture flasks, 37°C CO 2 nourish.

[0097] Establishment of cervical cancer tumor-bearing mouse model: TC-1 cells that have been cultured for more than 2 generations and have a growth density of 80-90% were taken. After washing, digestion, termination, and centrifugation, the cells were resuspended in PBS and counted with an automatic cell counter to adjust the cell concentration to 1×10 6 / mL; 100μL TC-1 cell solution was subcutaneously inoculated into the abdomen of the adaptively cultured mice. After about one week, subcutaneous tumors could be felt, indicating that the cervical cancer tumor-bearing mouse model was successfully established.

[0098] Immunization and grouping: According to the LM-LI-LM combined immunization method, 100 μL of the corresponding bacterial solution was inoculated into cervical cancer tumor-bearing mice by tail vein immunization or intratumoral injection every week. On the 7th day after the third immunotherapy, mice in groups A, B, and C (n=6) were selected for preliminary study of the anti-tumor mechanism. The remaining mice in groups A, B, C, D, and E (n=10) were selected for the treatment of death of mice and tumor volume of mice reached 2000mm. 3 Or the tumor-free state was stable for 7 days as the observation endpoint.

[0099] Determination of therapeutic effects in cervical cancer-bearing mice:

[0100] Tumor volume measurement: On the day of the first immunotherapy, the long and short diameters of the mouse tumors were measured with a vernier caliper to calculate the tumor volume (V = long diameter × 1 / 2 short diameter). 2 mm 3 ), measured once every other day, and the tumor volume of mice was continuously recorded.

[0101] Recording of survival rate and calculation of median survival time: The survival time of mice subcutaneously inoculated with TC-1 cells was recorded on day 0. When the tumor volume reached 2000 mm 3The mice were humanely killed at 1:10 pm and recorded as mouse death; when the tumors of the tumor-bearing mice were completely regressed and there was no recurrence, the mice were recorded as cured; when the mice in each group reached the observation endpoint, the median survival time of each group was calculated.

[0102] Determination of therapeutic effect of cervical cancer tumor-bearing mice: According to the combined immunization method of LM-LI-LM, 100 μL of the corresponding bacterial solution was inoculated into cervical cancer tumor-bearing mice by tail vein immunization or intratumoral injection every week for a total of 3 times. The changes in tumor volume and survival time of each group were recorded as follows: Figure 10-14 and Fig.15 . The tumor volume of mice in the PBS group (tail vein immunization, group A) showed a trend of continuous increase with the extension of survival time, and all reached the humanitarian sacrifice standard at 41 days, with a median survival time of 37 days. The tumor volume of mice in the vector strain group (tail vein immunization, group B) had the same change trend as that of group A, and all reached the survival endpoint at 43 days, with a median survival time of 37 days. The tumor volume of mice in the vaccine strain group (tail vein immunization, group C) also gradually increased with the increase of survival time in the early stage, but the rate of increase of tumor volume was significantly slower than that of groups A and B; the tumor volume of some mice gradually decreased or even completely disappeared with the increase of survival time, reaching the cure standard; the median survival time was 63 days, which was statistically significant compared with groups A and B (P<0.05); the cure rate of mouse tumors was 30%. The tumor volume of mice in the vaccine strain group (intratumoral injection immunization, group D) also showed an increasing trend in the early stage of observation, and the rate of tumor volume increase was also slower than that of groups A and B; the tumor volume of some mice showed a trend of gradual reduction in the middle stage, but eventually gradually increased with the increase of survival time, and all reached the end of survival at 57 days, with a median survival time of 45 days, which was longer than that of groups A and B, and the difference was statistically significant (P<0.05), but still lower than that of group C, and the difference was also statistically significant (P<0.05). The tumor volume of the unbalanced lethal system vaccine strain group (tail vein immunization, group E) also gradually increased with the increase of survival days, and the median survival time was also 63 days, which was not statistically significant compared with group C; the cure rate of mice was also 30%, the same as group C.

[0103] After testing the prepared cervical cancer therapeutic vaccine using various detection methods of the present invention, the following conclusions were finally obtained:

[0104] 1. The present invention successfully constructs vaccine strains of cervical cancer therapeutic vaccines (including Listeria monocytogenes cervical cancer therapeutic vaccines and Listeria ovis cervical cancer therapeutic vaccines.

[0105] 2. The complementing plasmids carried by the vaccine strains can all exist stably in vitro; bacteria carrying the complementing plasmids can grow in ordinary BH I culture medium, and their basic biochemical reactions are not much different from those of the attenuated strains; the vaccine strains can successfully express the target antigen protein and the expression level is higher than that of the unbalanced lethal vaccine strains.

[0106] 3. The vaccine strains do not cause serious damage to the liver, spleen, and lungs of mice, and each strain has no obvious effect on the weight of mice. Overall, it is relatively safe; the vaccine strains have good immunogenicity, and the combined immunization of LM-L I-LM is significantly better than the separate immunization of LM-LM-LM and L IL IL I.

[0107] 4. Vaccine strain combination immunization has a therapeutic effect on cervical cancer tumor-bearing mice, greatly prolonging the median survival time. The tail vein immunization method is significantly better than the intratumor injection method, but there is no significant difference from the unbalanced lethal vaccine strain combination immunization.

[0108] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A Listeria-based cervical cancer therapeutic vaccine, characterized in that: The cervical cancer therapeutic vaccine is prepared by the following method: The Amp resistance gene on the pCW-LMdal-Amp complementation plasmid was replaced with the asd nutritional gene by the method of inverse PCR and seamless cloning and connection, and the complementation plasmid pCW-LMdal-Ampfree without the Amp resistance gene was constructed; Insert the cervical cancer antigen gene into the complementing plasmid pCW-LMdal-Ampfree by enzyme digestion, PCR and seamless cloning to construct the complementing plasmid pCW-HPVXXX-LMdal-Ampfree; The complementing plasmid pCW-HPVXXX-LMdal-Ampfree is transferred into Listeria monocytogenes auxotrophic strain and / or Listeria ovis auxotrophic strain to obtain a candidate therapeutic vaccine for cervical cancer; Conduct biological testing and therapeutic effect screening on candidate cervical cancer therapeutic vaccines to obtain cervical cancer therapeutic vaccines.

2. The Listeria-based cervical cancer therapeutic vaccine according to claim 1, characterized in that: The cervical cancer antigen gene includes phly-SS-gp33-HA-E6E7-gp61.

3. The Listeria-based cervical cancer therapeutic vaccine according to claim 2, characterized in that: The biological detection and treatment effect screening of the candidate cervical cancer therapeutic vaccine to obtain the cervical cancer therapeutic vaccine comprises: PCR was used to detect the in vitro stability of the complementing plasmid pCW-HPVXXX-LMdal-Ampfree carried by the candidate cervical cancer therapeutic vaccine; The basic biological characteristics of the candidate therapeutic vaccine for cervical cancer were determined by biochemical reactions, in vitro growth, and hemolysis experiments; The secretory proteins and bacterial proteins of the cervical cancer therapeutic candidate vaccine were extracted, and the in vitro expression of the target protein of the cervical cancer therapeutic candidate vaccine was verified by WB experiment.

4. The Listeria-based cervical cancer therapeutic vaccine according to claim 3, characterized in that: The biological detection and treatment effect screening of the candidate cervical cancer therapeutic vaccine to obtain the cervical cancer therapeutic vaccine also includes: The LD50 of the candidate therapeutic vaccine for cervical cancer was determined by using the modified Coeur method. The safety of the candidate therapeutic vaccine for cervical cancer was evaluated by measuring the bacterial load in the liver / spleen / lung, the liver / spleen / lung organ index, the ALT and AST, the weight change of mice, and the preparation and observation of liver / spleen / lung pathological sections. The in vivo stability of the candidate therapeutic vaccine for cervical cancer was tested by PCR using colonies grown on BHI plates of liver / spleen / lung grinding drop plates at different time points as templates; Detection of CD4 in mouse spleen cells by flow cytometry + T cells and CD8 + IFN-γ in T cells + IL-2 + IL-12 + and TNF-α + The ratio of cells was used to determine the immunogenicity of the cervical cancer therapeutic vaccine candidate.

5. The Listeria-based cervical cancer therapeutic vaccine according to claim 4, characterized in that: The biological detection and treatment effect screening of the candidate cervical cancer therapeutic vaccine to obtain the cervical cancer therapeutic vaccine also includes: The cervical cancer tumor-bearing mouse model was established by subcutaneous injection of TC-1 cells, and the therapeutic effect of the candidate cervical cancer therapeutic vaccine was determined by LM-LI-LM combined immunization. The LM-LI-LM combination immunization method is the first immunization with Listeria monocytogenes cervical cancer therapeutic candidate vaccine, the second immunization with Listeria monocytogenes cervical cancer therapeutic candidate vaccine, and the third immunization with Listeria monocytogenes cervical cancer therapeutic candidate vaccine, and the interval between each immunization is 7 days.

6. The Listeria-based cervical cancer therapeutic vaccine according to claim 5, characterized in that: The biological detection and treatment effect screening of the candidate cervical cancer therapeutic vaccine to obtain the cervical cancer therapeutic vaccine also includes: Two immunization methods, intratumor injection and tail vein injection, were used to compare the effects of different immunization methods on the therapeutic efficacy of cervical cancer therapeutic vaccine candidates.

Citation Information

Patent Citations

  • HPV58 E6 / E7 fusion gene and therapeutic combined gene vaccine

    CN102277365A

  • Application of recombinant attenuated listeria in preparation of mesothelin high-expression cancer therapeutic vaccine

    CN108714210A

  • Cervical cancer therapeutic vaccine based on recombinant attenuating sheep listeria ivanovii

    CN108939064A

  • Mesothelin high-expression cancer therapeutic vaccine based on recombinant attenuated Listeria ivanovii

    CN108992664A

  • Cervical cancer vaccine capable of simultaneously targeting HPV16 L1 and HPV16 E5E6E7, and preparation method of cervical cancer vaccine

    CN111440811A

Cited By

  • Multivalent expression sheep listeria monocytogenes cervical cancer vaccine and preparation method thereof

    CN120230776A

  • Multivalently expressed sheep Listeria cervical cancer vaccine and preparation method thereof

    CN120230776B